Wed.May 01, 2024

article thumbnail

Funding Rehab: Knowing Your Options

Pharma Mirror

Addiction is affecting a large portion of people’s lives at the minute, but one of the things people often struggle with is knowing how to afford rehab. There’s a common misconception that it costs thousands upon thousands of pounds and is entirely unattainable for people in some circles of society. However, that’s precisely what it is, a misconception, and many options can help people, no matter how wealthy or poor they are.

130
130
article thumbnail

AstraZeneca admits Covid-19 vaccine may cause blood clots in “very rare” cases

Pharmaceutical Technology

AstraZeneca has maintained that while the vaccine may, in “very rare” cases, cause TTS, the casual mechanism for this effect remains unknown.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GSK raises forecasts on strong vaccine, HIV drug sales

Bio Pharma Dive

Sales of the shingles vaccine Shingrix and the RSV shot Arexvy helped fuel quarterly revenue totals that surpassed analyst expectations, though the company warned momentum could slow in the months ahead.

Sales 280
article thumbnail

Eli Lilly reports 67% increase in Q1 2024 net income

Pharmaceutical Technology

Eli Lilly has announced that its net income rose to $2.24bn in Q1 2024, a 67% increase from $1.34bn in the same period of 2023.

246
246
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

FTC targets ‘junk patents’ on Ozempic, other top drugs

Bio Pharma Dive

The move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate” patent listings by drugmakers to include top-selling medicines for weight loss, diabetes, asthma and COPD.

article thumbnail

Breakthrough Vaccine Shows High Protection Against Drug-Resistant Superbug in Mice

AuroBlog - Aurous Healthcare Clinical Trials blog

Scientists have developed a vaccine against a notorious drug-resistant superbug, targeting molecules on its surface that are also found on other bacteria and fungi.

More Trending

article thumbnail

India puts in place mechanisms to combat malaria as drug resistance poses serious challenge

AuroBlog - Aurous Healthcare Clinical Trials blog

India is now putting in place a mechanism to combat malaria as drug resistance poses a serious challenge. The treatment of malaria depends on timely diagnosis and efficient medication, especially artemisinin-based combination therapies (ACTs) that help in getting rid of parasites and relieve symptoms.

Drugs 168
article thumbnail

Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal

Bio Pharma Dive

The partnership follows Astellas’ investment in the biotech last year and adds to its portfolio of donor-derived cellular medicines.

Medicine 177
article thumbnail

Novartis and PeptiDream expand peptide discovery deal

Pharmaceutical Technology

Novartis and Japanese biopharmaceutical company PeptiDream have expanded their partnership for the discovery of peptides.

189
189
article thumbnail

May 1, 2024: PKIDS Pragmatic Trial to Be Featured in PCT Grand Rounds

Rethinking Clinical Trials

Dr. Gregory Tasian In this Friday’s PCT Grand Rounds, Gregory Tasian of the Children’s Hospital of Philadelphia will present “Comparative Effectiveness of Kidney Stone Surgery in Pediatric Patients: The PKIDS Trial.” The Grand Rounds session will be held on Friday, May 3, 2024, at 1:00 pm eastern. The Pediatric Kidney Stone (PKIDS) Care Improvement Network Trial is a patient-centered, pragmatic clinical trial comparing the effectiveness of stone clearance for 3 surgical m

Trials 143
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Chinese companies lead ADC pipeline

Pharmaceutical Technology

Antibody drug conjugates (ADCs) are a rapidly growing therapeutic class that leading data and analytics company GlobalData forecasts will generate more than $45bn in revenue by 2030.

Antibody 130
article thumbnail

Prevention revolution: How digital tools can help us get ahead of health problems

pharmaphorum

Discover how digital tools can provide insights to help us. Digital technology could be a game-changer that offers the elusive promise of tackling the root cause, not just the conditions themselves, when it comes to human health.

119
119
article thumbnail

ePRO vs eCOA: Understanding the nuances in clinical trials

Pharmaceutical Technology

Two such tools – electronic patient-reported outcomes (ePRO) and electronic clinical outcomes assessments (eCOA) – are often mentioned together. However, they serve distinct purposes and come with different considerations for clinical trial sponsors and contract research organisations (CROs). Understanding these differences is vital for selecting the right technology and provider to meet your trial needs.

article thumbnail

Emergent BioSolutions to cut 300 employees, shutter 2 facilities in restructuring launched under new CEO

Fierce Pharma

Just about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the CDMO-turned-biopharma company. | Merely about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the CDMO-turned-biopharma company. And it involves a major organizational restructuring.

120
120
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch

Pharmaceutical Technology

Last week, Roche released promising first-quarter (Q1) 2024 sales figures for VABYSMO, a vascular endothelial growth factor (VEGF) and angiopoietin-2 inhibitor for wet age-related macular degeneration (wAMD), diabetic macular oedema (DME), and macular oedema following retinal vein occlusion.

Sales 130
article thumbnail

Weight loss treatments bring in billions but capacity remains an issue

pharmaphorum

Explore the challenges in weight loss treatments despite the billions spent on clinical trials for weight loss drugs. Discover why capacity remains a critical issue in the industry.

article thumbnail

ePRO vs eCOA: Understanding the nuances in clinical trials

Pharmaceutical Technology

Two such tools – electronic patient-reported outcomes (ePRO) and electronic clinical outcomes assessments (eCOA) – are often mentioned together. However, they serve distinct purposes and come with different considerations for clinical trial sponsors and contract research organisations (CROs). Understanding these differences is vital for selecting the right technology and provider to meet your trial needs.

article thumbnail

Pfizer sets up DTC marketing platform as Q1 sales beat expectations

Fierce Pharma

Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen. | Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen. The company plans to sell products such as its COVID treatment Paxlovid and a migraine nasal spray in this way, it told the Financial Times.

Sales 114
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Enlaza Therapeutics secures $100m in Series A funding

Pharmaceutical Technology

Enlaza has raised $100m in a Series A funding round led by the Life Sciences group of JP Morgan Asset Management’s private capital unit.

article thumbnail

From banking to biotech - Renée Aguiar-Lucander's unique path in science

BioPharma Reporter

RenÃe Aguiar-Lucander, CEO of Calliditas, is driving the advancement and launch of TARPEYO â the companyâs medication targeting rare disease IgA nephropathy. We spoke with RenÃe about her journey from investment banking to science and the joy of bringing therapies to patients.

article thumbnail

Bayer and Evotec link to develop precision cardiology therapeutics

Pharmaceutical Technology

Bayer and Evotec have expanded collaboration to focus on the development of precision treatments for cardiovascular diseases (CVDs).

article thumbnail

MHRA ‘sandbox’ to pilot AI regulation will go live soon

pharmaphorum

The MHRA's regulatory sandbox for artificial intelligence as medical device technologies, AI-Airlock, will go live this spring, according to a new strategy document

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Magazine: Anticipation rises for RSV rollout as positive data emerges

Pharmaceutical Technology

In this issue: Following the RSV therapy and vaccine rollout, understanding molecular glues, using pharmacovigilance for active drug discovery, and more.

article thumbnail

FTC steps up campaign on junk patents with warning letters

pharmaphorum

FTC sends more warnings to pharma companies over 'junk' patents to protect drugs from generic competition, including Novo Nordisk's Ozempic.

article thumbnail

Janssen adopts J&J name as part of global rebranding effort

Pharmaceutical Technology

‘Janssen’ will no longer be seen on drug labels following the Johnson & Johnson brand name adoption.

Branding 162
article thumbnail

Biotts claims a first with insulin delivery across skin

pharmaphorum

Polish drug delivery company Biotts says it has demonstrated delivery of insulin across the skin for the first time without the use of an injection system.

Insulin 111
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Replay wins IND clearance for PRAME T cell cancer therapy

Pharmaceutical Technology

The US-based company is working alongside the University of Texas MD Anderson Cancer Center to fund the Phase I/II clinical trial.

article thumbnail

Jacobio plans bid for China’s KRAS market with safety edge

pharmaphorum

China's Jacobio Pharma is preparing to file its KRAS inhibitor glecirasib for approval, saying it could offer a safety advantage over current drugs in the class

Marketing 102
article thumbnail

Neurocrine bags FDA approval for new ‘sprinkle’ Ingrezza formulation

Pharmaceutical Technology

The sprinkle formulation of Ingrezza is approved as an alternative for Huntington’s patients who have difficulty swallowing.

article thumbnail

BIO survey to elucidate US biopharma’s reliance on Chinese CDMOs amid decoupling threats

Fierce Pharma

It’s no secret that U.S. biopharma companies rely on Chinese contractors to provide lab research and drug manufacturing services. | Facing a push for China-U.S. decoupling from Washington, the industry trade group BIO now wants to quantify the U.S.’s dependence on Chinese CDMOs through a survey.

article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.